

# Enrica Olivola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5521081/publications.pdf>

Version: 2024-02-01

23  
papers

440  
citations

687363

13  
h-index

752698

20  
g-index

24  
all docs

24  
docs citations

24  
times ranked

813  
citing authors

#	ARTICLE	IF	CITATIONS
1	Earlyâ€Stage Parkinson's Patients Show Selective Impairment in Reactive But Not Proactive Inhibition. <i>Movement Disorders</i> , 2020, 35, 409-418.	3.9	46
2	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	1.5	45
3	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of â€organicâ€neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	3.3	45
4	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. <i>Neurochemistry International</i> , 2017, 105, 58-63.	3.8	33
5	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	3.6	28
6	Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart. <i>PLoS ONE</i> , 2014, 9, e101763.	2.5	26
7	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	3.6	25
8	Autonomic Function Tests and <sc>MIBG</sc> in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 727-732.	3.9	23
9	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and Î±-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	2.2	22
10	Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: A challenge for the 6-OHDA model?. <i>Experimental Neurology</i> , 2010, 225, 294-301.	4.1	21
11	Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 67.	3.4	21
12	Continuous subcutaneous apomorphine infusion in Parkinsonâ€™s disease: causes of discontinuation and subsequent treatment strategies. <i>Neurological Sciences</i> , 2019, 40, 1917-1923.	1.9	21
13	CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. <i>Journal of Neural Transmission</i> , 2012, 119, 861-875.	2.8	16
14	Cerebrospinal-fluid Alzheimerâ€™s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinsonâ€™s Disease Patients. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 339-345.	1.4	12
15	Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2013, 34, 383-386.	1.9	10
16	Levodopaâ€carbidopa intrajejunal infusion in Parkinsonâ€™s disease: untangling the role of age. <i>Journal of Neurology</i> , 2021, 268, 1728-1737.	3.6	9
17	Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinsonâ€™s Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 640603.	3.5	8
18	Does fatigue in Parkinsonâ€™s disease correlate with autonomic nervous system dysfunction?. <i>Neurological Sciences</i> , 2018, 39, 2169-2174.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	1.9	5
20	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq0 0 0 rgBT/Overlap 10 Tf 50	1.9	5
21	Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer&#8217;s Disease and Possible Detection of Overlaps with Frailty Process. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 538-546.	1.4	5
22	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 32-36.	2.2	4
23	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinsonâ€™s Disease. <i>Frontiers in Neurology</i> , 2015, 6, 261.	2.4	2